Form 4: BioCardia CFO's Equity Compensation & Vesting

BioCardia's Chief Financial Officer, David McClung, reported the vesting of restricted stock units and the grant of new stock options as part of his compensation.

Summary

• Chief Financial Officer David McClung acquired 58,276 shares of BioCardia, Inc. common stock through the vesting of Restricted Stock Units (RSUs) on December 8, 2025, at a price of $1.37 per share.
• 29,339 shares were withheld by BioCardia, Inc. to satisfy income tax, withholding, and remittance obligations related to the RSU vesting, which does not represent a sale by the Reporting Person.
• McClung was granted 27,000 stock options with an exercise price of $1.37, which will vest and become exercisable as to 1/48th of the shares on January 8, 2026, and each month thereafter, subject to his continued service.
• Following these transactions, McClung directly beneficially owns 76,887 shares of common stock and 46,340 stock options.

Sentiment

Score: 7

Explanation: The filing indicates a routine executive compensation event, increasing the CFO's beneficial ownership and aligning his long-term incentives with the company's performance, which is generally a positive signal for investors.

Positives

• CFO David McClung's direct beneficial ownership of common stock increased to 76,887 shares after the RSU vesting, demonstrating continued alignment with shareholder interests.
• The grant of 27,000 stock options further incentivizes the CFO's long-term commitment and performance, with vesting tied to continued service over 48 months.

Negatives

• 29,339 shares were withheld for tax obligations, reducing the immediate net share gain from the RSU vesting.

Future Outlook

The vesting schedule for the newly granted stock options, extending monthly over 48 months from January 8, 2026, suggests a long-term incentive structure for the Chief Financial Officer, aligning his interests with the company's sustained performance.

Industry Context

This filing reflects routine executive compensation practices within the biotechnology industry, where equity awards like RSUs and stock options are common tools to align management incentives with long-term shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options as a component of executive compensation is a standard practice across the biotechnology and broader public company landscape, comparable to compensation structures seen at companies like Gilead Sciences or Amgen, which also utilize equity awards to incentivize key personnel and promote retention.

Related Party Transactions

• The transactions involve the grant and vesting of equity compensation to a key executive, which are standard related-party dealings in the context of executive remuneration.

Stakeholder Impact

• Shareholders benefit from increased alignment of the Chief Financial Officer's interests with long-term company performance through equity ownership and future vesting incentives.

Next Steps

• The stock options granted will continue to vest monthly over the next 48 months, subject to the CFO's continued service.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation through RSU vesting and new stock option grants. While the increase in the CFO's beneficial ownership is a minor positive, demonstrating continued alignment with shareholder interests, it does not present new fundamental information to warrant a change in investment recommendation. Therefore, a 'hold' recommendation is maintained, pending further operational or financial updates.

Keywords

BioCardia, BCDA, Form 4, insider transaction, executive compensation, restricted stock units, RSU, stock options, beneficial ownership, David McClung, CFO